In a 61-year-old patient with an estimated glomerular filtration rate of 50 mL/min/1.73 m² who needs antihypertensive therapy, is losartan appropriate and how should it be started and monitored?

Losartan is Appropriate and Should Be Started at 50 mg Daily

For a 61-year-old patient with eGFR 50 mL/min/1.73 m², losartan is an appropriate antihypertensive choice and requires no dose adjustment at this level of kidney function. The standard starting dose of 50 mg once daily should be used, with potential titration to 100 mg daily based on blood pressure response 1.

Why Losartan is Appropriate at This eGFR

With an eGFR of 50 mL/min/1.73 m² (CKD stage G3a), this patient falls well within the safe range for losartan use. No dose adjustment is necessary in patients with renal impairment unless they are also volume depleted 1. The FDA label explicitly states that patients with renal insufficiency have elevated plasma concentrations of losartan and its active metabolite compared to those with normal renal function, but dosing remains unchanged 1.

The 2024 KDIGO guidelines strongly support renin-angiotensin system inhibitors (RASi) like losartan for patients with CKD, particularly if albuminuria is present 2. Even without knowing this patient's albuminuria status, losartan remains reasonable for hypertension management in CKD (Practice Point 3.6.6) 2.

Starting and Titration Protocol

Initial Dosing

• Start with losartan 50 mg once daily 1
• Consider 25 mg daily only if the patient has possible intravascular depletion (e.g., currently on diuretic therapy) 1
• The usual dose can be increased to a maximum of 100 mg once daily as needed for blood pressure control 1

Monitoring Schedule

Within 2-4 weeks of initiation, check:

• Blood pressure
• Serum creatinine
• Serum potassium 2, 3

The 2-4 week timeframe depends on current GFR and baseline potassium—at eGFR 50, checking at 2-3 weeks is prudent 2.

Safety Parameters and When to Adjust

Continue losartan UNLESS:

• Serum creatinine rises >30% within 4 weeks of initiation or dose increase 2, 3
• Symptomatic hypotension occurs despite management 2
• Uncontrolled hyperkalemia persists despite medical treatment 2

Important: Hyperkalemia Management

Do not automatically discontinue losartan for hyperkalemia. Hyperkalemia associated with RASi use can often be managed by measures to reduce serum potassium levels rather than decreasing the dose or stopping the medication 2, 3. This is a common pitfall—clinicians prematurely discontinue beneficial RASi therapy when potassium-lowering strategies should be attempted first.

Long-term Considerations

Continue Through CKD Progression

Continue losartan even when eGFR falls below 30 mL/min/1.73 m² (Practice Point 3.6.7) 2. This represents a significant shift from older practice patterns and reflects evidence that RASi benefits persist in advanced CKD.

Target Dosing

RASi should be administered using the highest approved dose that is tolerated to achieve proven benefits, as clinical trial benefits were achieved using these doses 2, 3. For losartan, this means titrating toward 100 mg daily if blood pressure is not controlled and the medication is well-tolerated.

Blood Pressure Targets

Based on 2024 KDIGO and 2025 AHA/ACC guidelines, target blood pressure is <130/80 mm Hg using standardized office measurement 2, 4. The 2021 KDIGO guideline even suggests targeting SBP <120 mm Hg when tolerated using standardized measurement 3, though this more aggressive target requires careful patient selection.

Additional Monitoring Considerations

Research evidence shows that losartan preserves renal function in CKD patients. In a study of normotensive Chinese patients with stage 3 CKD, losartan 50 mg daily maintained stable eGFR over 12 months while significantly reducing proteinuria 5. Another study demonstrated that losartan 100 mg daily was more effective than 50 mg for both renoprotection and blood pressure reduction in diabetic nephropathy 6.

Common Pitfalls to Avoid

1. Don't reduce the dose preemptively based solely on eGFR 50—no adjustment is needed 1
2. Don't stop for mild creatinine elevation (<30% increase)—this is expected and acceptable 2
3. Don't discontinue immediately for hyperkalemia—implement potassium-lowering strategies first 2
4. Don't use subtherapeutic doses—titrate to maximum tolerated dose for optimal benefit 2
5. Avoid in pregnancy—losartan is Pregnancy Category D and must be discontinued if pregnancy is detected 1